Gossamer Bio to Attend Investor Conferences in November

Gossamer Bio, a late-stage biopharmaceutical company, will participate in two investor conferences in November: UBS Global Healthcare Conference and Guggenheim Securities Healthcare Innovation Conference. The company will present at the latter event and hold one-on-one meetings at both conferences. Gossamer Bio is focused on developing seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.